B-intervention	0	9	Tamoxifen
O	10	13	for
O	14	24	prevention
O	25	27	of
O	28	34	breast
O	35	41	cancer
O	41	42	:
O	43	49	report
O	50	52	of
O	53	56	the
O	57	65	National
O	66	74	Surgical
O	75	83	Adjuvant
O	84	90	Breast
O	91	94	and
O	95	100	Bowel
O	101	108	Project
O	109	110	P
O	110	111	-
O	111	112	1
O	113	118	Study
O	118	119	.

O	120	123	The
O	124	131	finding
O	132	134	of
O	135	136	a
O	137	145	decrease
O	146	148	in
O	149	162	contralateral
O	163	169	breast
O	170	176	cancer
O	177	186	incidence
O	187	196	following
O	197	206	tamoxifen
O	207	221	administration
O	222	225	for
O	226	234	adjuvant
O	235	242	therapy
O	243	246	led
O	247	249	to
O	250	253	the
O	254	261	concept
O	262	266	that
O	267	270	the
O	271	275	drug
O	276	281	might
O	282	286	play
O	287	288	a
O	289	293	role
O	294	296	in
O	297	303	breast
O	304	310	cancer
O	311	321	prevention
O	321	322	.

O	323	325	To
O	326	330	test
O	331	335	this
O	336	346	hypothesis
O	346	347	,
O	348	351	the
O	352	360	National
O	361	369	Surgical
O	370	378	Adjuvant
O	379	385	Breast
O	386	389	and
O	390	395	Bowel
O	396	403	Project
O	404	413	initiated
O	414	417	the
O	418	424	Breast
O	425	431	Cancer
O	432	442	Prevention
O	443	448	Trial
O	449	450	(
O	450	451	P
O	451	452	-
O	452	453	1
O	453	454	)
O	455	457	in
O	458	462	1992
O	462	463	.

O	464	469	Women
O	470	471	(
O	471	472	N
O	472	473	=
B-total-participants	473	478	13388
O	478	479	)
B-eligibility	480	482	at
I-eligibility	483	492	increased
I-eligibility	493	497	risk
I-eligibility	498	501	for
I-eligibility	502	508	breast
I-eligibility	509	515	cancer
I-eligibility	516	523	because
I-eligibility	524	528	they
I-eligibility	529	530	1
I-eligibility	530	531	)
I-eligibility	532	536	were
I-eligibility	537	539	60
I-eligibility	540	545	years
I-eligibility	546	548	of
I-eligibility	549	552	age
I-eligibility	553	555	or
I-eligibility	556	561	older
I-eligibility	561	562	,
I-eligibility	563	564	2
I-eligibility	564	565	)
I-eligibility	566	570	were
I-eligibility	571	573	35
I-eligibility	573	574	-
I-eligibility	574	576	59
I-eligibility	577	582	years
I-eligibility	583	585	of
I-eligibility	586	589	age
I-eligibility	590	594	with
I-eligibility	595	596	a
I-eligibility	597	598	5
I-eligibility	598	599	-
I-eligibility	599	603	year
I-eligibility	604	613	predicted
I-eligibility	614	618	risk
I-eligibility	619	622	for
I-eligibility	623	629	breast
I-eligibility	630	636	cancer
I-eligibility	637	639	of
I-eligibility	640	642	at
I-eligibility	643	648	least
I-eligibility	649	650	1
I-eligibility	650	651	.
I-eligibility	651	653	66
I-eligibility	653	654	%
I-eligibility	654	655	,
I-eligibility	656	658	or
I-eligibility	659	660	3
I-eligibility	660	661	)
I-eligibility	662	665	had
I-eligibility	666	667	a
I-eligibility	668	675	history
I-eligibility	676	678	of
I-eligibility	679	686	lobular
I-eligibility	687	696	carcinoma
I-eligibility	697	699	in
I-eligibility	700	704	situ
O	705	709	were
O	710	718	randomly
O	719	727	assigned
O	728	730	to
O	731	738	receive
B-control	739	746	placebo
O	747	748	(
O	748	749	n
O	749	750	=
B-control-participants	750	754	6707
O	754	755	)
O	756	758	or
O	759	761	20
O	762	764	mg
O	764	765	/
O	765	768	day
O	769	778	tamoxifen
O	779	780	(
O	780	781	n
O	781	782	=
B-intervention-participants	782	786	6681
O	786	787	)
O	788	791	for
O	792	793	5
O	794	799	years
O	799	800	.

O	801	805	Gail
O	805	806	'
O	806	807	s
O	808	817	algorithm
O	817	818	,
O	819	824	based
O	825	827	on
O	828	829	a
O	830	842	multivariate
O	843	851	logistic
O	852	862	regression
O	863	868	model
O	869	874	using
O	875	887	combinations
O	888	890	of
O	891	895	risk
O	896	903	factors
O	903	904	,
O	905	908	was
O	909	913	used
O	914	916	to
O	917	925	estimate
O	926	929	the
O	930	941	probability
O	942	943	(
O	943	947	risk
O	947	948	)
O	949	951	of
O	952	962	occurrence
O	963	965	of
O	966	972	breast
O	973	979	cancer
O	980	984	over
O	985	989	time
O	989	990	.

O	991	1000	Tamoxifen
B-outcome	1001	1008	reduced
I-outcome	1009	1012	the
I-outcome	1013	1017	risk
I-outcome	1018	1020	of
I-outcome	1021	1029	invasive
I-outcome	1030	1036	breast
I-outcome	1037	1043	cancer
O	1044	1046	by
O	1047	1049	49
O	1049	1050	%
O	1051	1052	(
O	1052	1055	two
O	1055	1056	-
O	1056	1061	sided
O	1062	1063	P
O	1063	1064	<
O	1064	1065	.
O	1065	1070	00001
O	1070	1071	)
O	1071	1072	,
O	1073	1077	with
O	1078	1088	cumulative
O	1089	1098	incidence
O	1099	1106	through
O	1107	1109	69
O	1110	1116	months
O	1117	1119	of
O	1120	1126	follow
O	1126	1127	-
O	1127	1129	up
O	1130	1132	of
B-cv-bin-abs	1133	1135	43
I-cv-bin-abs	1135	1136	.
I-cv-bin-abs	1136	1137	4
O	1138	1144	versus
B-iv-bin-abs	1145	1147	22
I-iv-bin-abs	1147	1148	.
I-iv-bin-abs	1148	1149	0
O	1150	1153	per
B-intervention-participants	1154	1158	1000
O	1159	1164	women
O	1165	1167	in
O	1168	1171	the
O	1172	1179	placebo
O	1180	1183	and
O	1184	1193	tamoxifen
O	1194	1200	groups
O	1200	1201	,
O	1202	1214	respectively
O	1214	1215	.

O	1216	1219	The
B-outcome	1220	1229	decreased
I-outcome	1230	1234	risk
O	1235	1243	occurred
O	1244	1246	in
O	1247	1252	women
O	1253	1257	aged
O	1258	1260	49
O	1261	1266	years
O	1267	1269	or
O	1270	1277	younger
O	1278	1279	(
B-iv-bin-percent	1279	1281	44
I-iv-bin-percent	1281	1282	%
O	1282	1283	)
O	1283	1284	,
O	1285	1287	50
O	1287	1288	-
O	1288	1290	59
O	1291	1296	years
O	1297	1298	(
B-iv-bin-percent	1298	1300	51
I-iv-bin-percent	1300	1301	%
O	1301	1302	)
O	1302	1303	,
O	1304	1307	and
O	1308	1310	60
O	1311	1316	years
O	1317	1319	or
O	1320	1325	older
O	1326	1327	(
B-iv-bin-percent	1327	1329	55
I-iv-bin-percent	1329	1330	%
O	1330	1331	)
O	1331	1332	;
O	1333	1337	risk
O	1338	1341	was
O	1342	1346	also
O	1347	1354	reduced
O	1355	1357	in
O	1358	1363	women
O	1364	1368	with
O	1369	1370	a
O	1371	1378	history
O	1379	1381	of
O	1382	1389	lobular
O	1390	1399	carcinoma
O	1400	1402	in
O	1403	1407	situ
O	1408	1409	(
B-iv-bin-percent	1409	1411	56
I-iv-bin-percent	1411	1412	%
O	1412	1413	)
O	1414	1416	or
O	1417	1425	atypical
O	1426	1437	hyperplasia
O	1438	1439	(
B-iv-bin-percent	1439	1441	86
I-iv-bin-percent	1441	1442	%
O	1442	1443	)
O	1444	1447	and
O	1448	1450	in
O	1451	1456	those
O	1457	1461	with
O	1462	1465	any
O	1466	1474	category
O	1475	1477	of
O	1478	1487	predicted
O	1488	1489	5
O	1489	1490	-
O	1490	1494	year
O	1495	1499	risk
O	1499	1500	.

O	1501	1510	Tamoxifen
B-outcome	1511	1518	reduced
I-outcome	1519	1522	the
I-outcome	1523	1527	risk
I-outcome	1528	1530	of
I-outcome	1531	1542	noninvasive
I-outcome	1543	1549	breast
I-outcome	1550	1556	cancer
O	1557	1559	by
B-iv-bin-percent	1560	1562	50
I-iv-bin-percent	1562	1563	%
O	1564	1565	(
O	1565	1568	two
O	1568	1569	-
O	1569	1574	sided
O	1575	1576	P
O	1576	1577	<
O	1577	1578	.
O	1578	1581	002
O	1581	1582	)
O	1582	1583	.

O	1584	1593	Tamoxifen
O	1594	1601	reduced
O	1602	1605	the
B-outcome	1606	1616	occurrence
I-outcome	1617	1619	of
I-outcome	1620	1628	estrogen
I-outcome	1629	1637	receptor
I-outcome	1637	1638	-
I-outcome	1638	1646	positive
I-outcome	1647	1653	tumors
O	1654	1656	by
B-iv-bin-percent	1657	1659	69
I-iv-bin-percent	1659	1660	%
O	1660	1661	,
O	1662	1665	but
O	1666	1668	no
O	1669	1679	difference
O	1680	1682	in
O	1683	1686	the
O	1687	1697	occurrence
O	1698	1700	of
O	1701	1709	estrogen
O	1710	1718	receptor
O	1718	1719	-
O	1719	1727	negative
O	1728	1734	tumors
O	1735	1738	was
O	1739	1743	seen
O	1743	1744	.

O	1745	1754	Tamoxifen
O	1755	1769	administration
O	1770	1773	did
O	1774	1777	not
O	1778	1783	alter
O	1784	1787	the
O	1788	1795	average
O	1796	1802	annual
B-outcome	1803	1807	rate
I-outcome	1808	1810	of
I-outcome	1811	1819	ischemic
I-outcome	1820	1825	heart
I-outcome	1826	1833	disease
O	1833	1834	;
O	1835	1842	however
O	1842	1843	,
O	1844	1845	a
O	1846	1855	reduction
O	1856	1858	in
B-outcome	1859	1862	hip
I-outcome	1862	1863	,
I-outcome	1864	1870	radius
I-outcome	1871	1872	(
I-outcome	1872	1878	Colles
I-outcome	1878	1879	'
I-outcome	1879	1880	)
I-outcome	1880	1881	,
I-outcome	1882	1885	and
I-outcome	1886	1891	spine
I-outcome	1892	1901	fractures
O	1902	1905	was
O	1906	1914	observed
O	1914	1915	.

O	1916	1919	The
B-outcome	1920	1924	rate
I-outcome	1925	1927	of
I-outcome	1928	1939	endometrial
I-outcome	1940	1946	cancer
O	1947	1950	was
O	1951	1960	increased
O	1961	1963	in
O	1964	1967	the
O	1968	1977	tamoxifen
O	1978	1983	group
O	1984	1985	(
O	1985	1989	risk
O	1990	1995	ratio
O	1996	1997	=
O	1998	1999	2
O	1999	2000	.
O	2000	2002	53
O	2002	2003	;
O	2004	2006	95
O	2006	2007	%
O	2008	2018	confidence
O	2019	2027	interval
O	2028	2029	=
O	2030	2031	1
O	2031	2032	.
O	2032	2034	35
O	2034	2035	-
O	2035	2036	4
O	2036	2037	.
O	2037	2039	97
O	2039	2040	)
O	2040	2041	;
O	2042	2046	this
O	2047	2056	increased
O	2057	2061	risk
O	2062	2070	occurred
O	2071	2084	predominantly
O	2085	2087	in
O	2088	2093	women
O	2094	2098	aged
O	2099	2101	50
O	2102	2107	years
O	2108	2110	or
O	2111	2116	older
O	2116	2117	.

O	2118	2121	All
O	2122	2133	endometrial
O	2134	2141	cancers
O	2142	2144	in
O	2145	2148	the
O	2149	2158	tamoxifen
O	2159	2164	group
O	2165	2169	were
O	2170	2175	stage
O	2176	2177	I
O	2178	2179	(
O	2179	2188	localized
O	2189	2196	disease
O	2196	2197	)
O	2197	2198	;
O	2199	2201	no
B-outcome	2202	2213	endometrial
I-outcome	2214	2220	cancer
I-outcome	2221	2227	deaths
O	2228	2232	have
O	2233	2241	occurred
O	2242	2244	in
O	2245	2249	this
O	2250	2255	group
O	2255	2256	.

O	2257	2259	No
B-outcome	2260	2265	liver
I-outcome	2266	2273	cancers
I-outcome	2274	2276	or
I-outcome	2277	2285	increase
I-outcome	2286	2288	in
I-outcome	2289	2294	colon
I-outcome	2294	2295	,
I-outcome	2296	2302	rectal
I-outcome	2302	2303	,
I-outcome	2304	2311	ovarian
I-outcome	2311	2312	,
I-outcome	2313	2315	or
I-outcome	2316	2321	other
I-outcome	2322	2328	tumors
O	2329	2332	was
O	2333	2341	observed
O	2342	2344	in
O	2345	2348	the
O	2349	2358	tamoxifen
O	2359	2364	group
O	2364	2365	.

O	2366	2369	The
B-outcome	2370	2375	rates
I-outcome	2376	2378	of
I-outcome	2379	2385	stroke
I-outcome	2385	2386	,
I-outcome	2387	2396	pulmonary
I-outcome	2397	2405	embolism
I-outcome	2405	2406	,
I-outcome	2407	2410	and
I-outcome	2411	2415	deep
I-outcome	2415	2416	-
I-outcome	2416	2420	vein
I-outcome	2421	2431	thrombosis
O	2432	2436	were
O	2437	2445	elevated
O	2446	2448	in
O	2449	2452	the
O	2453	2462	tamoxifen
O	2463	2468	group
O	2468	2469	;
O	2470	2475	these
O	2476	2482	events
O	2483	2491	occurred
O	2492	2496	more
O	2497	2507	frequently
O	2508	2510	in
O	2511	2516	women
O	2517	2521	aged
O	2522	2524	50
O	2525	2530	years
O	2531	2533	or
O	2534	2539	older
O	2539	2540	.

O	2541	2550	Tamoxifen
O	2551	2560	decreases
O	2561	2564	the
B-outcome	2565	2574	incidence
I-outcome	2575	2577	of
I-outcome	2578	2586	invasive
I-outcome	2587	2590	and
I-outcome	2591	2602	noninvasive
I-outcome	2603	2609	breast
I-outcome	2610	2616	cancer
O	2616	2617	.

O	2618	2625	Despite
O	2626	2630	side
O	2631	2638	effects
O	2639	2648	resulting
O	2649	2653	from
O	2654	2668	administration
O	2669	2671	of
O	2672	2681	tamoxifen
O	2681	2682	,
O	2683	2686	its
O	2687	2690	use
O	2691	2693	as
O	2694	2695	a
O	2696	2702	breast
O	2703	2709	cancer
O	2710	2720	preventive
O	2721	2726	agent
O	2727	2729	is
O	2730	2741	appropriate
O	2742	2744	in
O	2745	2749	many
O	2750	2755	women
O	2756	2758	at
O	2759	2768	increased
O	2769	2773	risk
O	2774	2777	for
O	2778	2781	the
O	2782	2789	disease
O	2789	2790	.
